

Quality-of-Life Tradeoffs for Hepatitis C Treatment: Do

Medical Decision Making

28, 233-242

DOI: 10.1177/0272989x07311753

Citation Report

#	ARTICLE	IF	CITATIONS
1	Can urban methadone patients complete health utility assessments?. Patient Education and Counseling, 2008, 71, 302-307.	1.0	1
2	Respect for Rational Autonomy. Kennedy Institute of Ethics Journal, 2009, 19, 339-366.	0.3	11
3	Treatment of hepatitis C infection for current or former substance abusers in a community setting. Journal of Viral Hepatitis, 2009, 16, 557-567.	1.0	20
4	Quality of life considerations for patients with chronic hepatitis C. Journal of Viral Hepatitis, 2009, 16, 605-611.	1.0	90
5	The Use of QALYs in Clinical and Patient Decision-Making: Issues and Prospects. Value in Health, 2009, 12, S27-S30.	0.1	118
6	A Multinational Study of Health State Preference Values Associated with Chronic Myelogenous Leukemia. Value in Health, 2010, 13, 103-111.	0.1	34
7	Patients' Preferences for Treatment of Hepatitis C. Medical Decision Making, 2010, 30, 45-57.	1.2	35
8	Hepatitis C Treatment Experiences and Decision Making Among Patients Living With HIV Infection. Journal of the Association of Nurses in AIDS Care, 2010, 21, 63-74.	0.4	18
9	Hepatitis C management. European Journal of Gastroenterology and Hepatology, 2011, 23, 32-40.	0.8	8
10	Patient preferences and assessment of likely adherence to hepatitis C virus treatment. Journal of Viral Hepatitis, 2011, 18, 619-627.	1.0	34
11	The Era of Direct-Acting Antivirals: The Evolving Role of Interferon and Ribavirin for the Treatment of chronic Hepatitis C. Clinical Medicine Insights Therapeutics, 2012, 4, CMT.S6792.	0.4	0
12	Impact of Treatment Attributes of Peginterferon for Hepatitis C on Quality of Life and Treatment Preference. Health Outcomes Research in Medicine, 2012, 3, e153-e167.	0.6	4
13	Methods and issues associated with the use of quality-adjusted life-years. Expert Review of Pharmacoeconomics and Outcomes Research, 2012, 12, 105-114.	0.7	16
14	Patients' Willingness to Accept the Risks and Benefits of New Treatments for Chronic Hepatitis C Virus Infection. Patient, 2012, 5, 265-278.	1.1	12
15	Patient Preferences Versus Physicians' Judgement: Does it Make a Difference in Healthcare Decision Making?. Applied Health Economics and Health Policy, 2013, 11, 163-180.	1.0	162
16	The Hepatitis C Cascade of Care: Identifying Priorities to Improve Clinical Outcomes. PLoS ONE, 2014, 9, e97317.	1.1	109
17	The cost-effectiveness of improved hepatitis C virus therapies in HIV/hepatitis C virus coinfecting patients. Aids, 2014, 28, 365-376.	1.0	20
18	Cost-effectiveness of rapid hepatitis C virus (HCV) testing and simultaneous rapid HCV and HIV testing in substance abuse treatment programs. Addiction, 2015, 110, 129-143.	1.7	39

#	ARTICLE	IF	CITATIONS
19	Variations in Physician Attitudes Regarding ADHD and Their Association With Prescribing Practices. <i>Journal of Attention Disorders</i> , 2015, 19, 569-577.	1.5	8
20	The Cost-Effectiveness of Sofosbuvir-Based Regimens for Treatment of Hepatitis C Virus Genotype 2 or 3 Infection. <i>Annals of Internal Medicine</i> , 2015, 162, 619-629.	2.0	92
21	Understanding Patient Preferences in Medication Nonadherence: A Review of Stated Preference Data. <i>Patient</i> , 2015, 8, 385-395.	1.1	18
22	Clinical impact of treatment timing for chronic hepatitis C infection: a decision model. <i>Journal of Viral Hepatitis</i> , 2015, 22, 630-638.	1.0	8
23	Listening to both sides: A qualitative comparison between patients with hepatitis C and their healthcare professionals' perceptions of the facilitators and barriers to hepatitis C treatment adherence and completion. <i>Journal of Health Psychology</i> , 2017, 22, 1300-1311.	1.3	19
24	Preferences for antiviral therapy of chronic hepatitis C: a discrete choice experiment. <i>European Journal of Health Economics</i> , 2017, 18, 155-165.	1.4	48
25	Cost Effectiveness and Cost Containment in the Era of Interferon-Free Therapies to Treat Hepatitis C Virus Genotype 1. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofw266.	0.4	14
26	Cost-effectiveness of hepatitis C screening and treatment linkage intervention in US methadone maintenance treatment programs. <i>Drug and Alcohol Dependence</i> , 2018, 185, 411-420.	1.6	22
27	Listening to both sides: A qualitative comparison between patients with hepatitis C and their healthcare professionals' perceptions of the facilitators and barriers to hepatitis C treatment adherence and completion. <i>Journal of Health Psychology</i> , 2018, 23, 1720-1731.	1.3	7
28	Cost-Effectiveness of One-Time Hepatitis C Screening Strategies Among Adolescents and Young Adults in Primary Care Settings. <i>Clinical Infectious Diseases</i> , 2018, 66, 376-384.	2.9	62
29	Cost-effectiveness of Hepatitis C Virus Treatment Models for People Who Inject Drugs in Opioid Agonist Treatment Programs. <i>Clinical Infectious Diseases</i> , 2020, 70, 1397-1405.	2.9	13
30	International Handbook of Health Expectancies. <i>International Handbooks of Population</i> , 2020, , .	0.2	21
31	Patients' Willingness to Accept the Risks and Benefits of New Treatments for Chronic Hepatitis C Virus Infection. <i>Patient</i> , 2012, 5, 265-278.	1.1	12
32	Utility of Health Expectancy When Evaluating Health Care Systems. <i>International Handbooks of Population</i> , 2020, , 201-216.	0.2	0